Intuitive Surgical, Inc, headquartered in Sunnyvale, California. (ISRG) has a market capitalization of $204.14 billion and specializes in the medical equipment and property assets industry. The company develops, manufactures and sells innovative products that enable physicians and healthcare providers to improve the quality and accessibility of minimally invasive care.
Companies over $200 billion are commonly referred to as “megacap stocks,” and intuitively fit into categories, indicating their size, influence and market presence in the medical device industry. As the dominant player in robotic surgery, he holds a strong competitive moat due to high switching costs and continuous innovation. With the increasing global adoption of robot-assisted procedures, ISRG is suitable for long-term growth.
Active Investors: Free newsletter behind the hottest stock headlines to uncover new trade ideas
Despite the company's innovative products, it fell 8% since reaching its 52-week high of $616 on January 23rd. However, the share price has increased 4.7% over the past three months compared to the periphery of Vanguard Health Care Index Fund stock (VHT) over the same time frame.
www.barchart.com
Furthermore, in the long term, ISRG shares have skyrocketed at 17.3% over the past six months and 42.5% over the past 52 weeks. In contrast, VHT has declined 5.3% over the past six months and has skyrocketed 1.2% over the past year.
Despite some recent changes, ISRG has been trading above the 50-day moving average since mid-May 2024, exceeding the 200-day moving average from the past year.
www.barchart.com
The powerful performance of intuitive surgical surgeries over the past year stems from leadership in robotic surgery with the Da Vinci system, a robust repeat revenue model driven by disposable equipment and service contracts, and relentless innovation in minimal intrusion surgical techniques.
On January 15th, the company's shares surged 7.7% after a preliminary fourth-quarter earnings release. ISRG announced a 25% increase in reserve revenue. This reached $2.41 billion. Additionally, its EPS was $1.93, 36.9% ahead of the Wall Street EPS estimate.
Meanwhile, in the highly competitive medical device industry, ISRG rival Abbott Institute (ABT) has also shown a rapid growth of 22.3% over the past six months and 18.2% over the past 52 days.
Additionally, Wall Street analysts remain strong and bullish on the ISRG outlook. The stock holds a consensus “strong buy” rating from 27 analysts that cover it. The average target of $642.40 suggests a potential rise of 13.3% from current market prices.
On the date of publication, Kritika Sarmah had no position (directly or indirectly) in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. For more information, see BarChart's disclosure policy.
More news from the bar chart
The views and opinions expressed herein are the views and opinions of the authors and are not necessarily Nasdaq, Inc. It does not reflect the opinions of
